Although advances in synthesis have led to production of both natural rocaglates and novel rocaglamide analogs, few, if any, of these compounds have been investigated for activity as TRAIL sensitizers and neither ROC nor its analogs have been widely assessed in the context of RCC cells. Here, TNFSF10 is linked to renal cell carcinoma.